Clinical Trial: Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148128) titled 'Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.' on June 25.

Brief Summary: This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

Study Start Date: July 28

Study Type: INTERVENTIONAL

Condition: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cance...